Approval of expanded indication based predominately on real-world data NEW YORK--(BUSINESS WIRE)-- Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a ...

Pfizer is alleging that Aurobindo and Dr. Reddy's were planning separately to come out with generic versions of Ibrance before expiration of its patent. ... in dosage strengths of 75 mg, ...

Pfizer, Inc.’s PFE blockbuster medicine Ibrance gained FDA approval for the treatment of breast cancer in men, thereby expanding the drug’s eligible patient population. Ibrance, CDK 4/6 ...

Richard Finn transferred to UCLA as an undergraduate freshman from UC San Diego in the late 1970s to be closer to home after his mother died of breast cancer when he was a college freshman.

The drug, IBRANCE (palbociclib) was studied in 165 post-menopausal breast cancer patients with advanced ER+, HER2- disease who had received no prior systemic therapy for their metastatic disease.

A 28-day supply of the 600-mg dose will cost $10,950, ... While Kisqali may beat Ibrance on price, though, when it comes to safety and convenience, ...

EvaluatePharma thinks Ibrance will become a mega-blockbuster with sales of $6bn-plus in 2022, consigning its rivals into a fight for second place. With the approval Novartis has however pulled ahead ...

Pfizer, Inc.’s PFE blockbuster medicine Ibrance gained FDA approval for the treatment of breast cancer in men, thereby expanding the drug’s eligible patient population. Ibrance, CDK 4/6 inhibitor, can ...

Pfizer, Inc. 's PFE blockbuster medicine Ibrance gained FDA approval for the treatment of breast cancer in men, thereby expanding the drug's eligible patient population. Ibrance, CDK 4/6 inhibitor ...